The collaboration with Broad Clinical Labs is likely to enhance Illumina's capabilities in single-cell research, a growing field in biotechnology. This could lead to advancements in disease modeling and drug development, potentially increasing demand for Illumina's products and services, thus positively impacting its stock price.